STN: BL 125106
Proper Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Manufacturer: GlaxoSmithKline Biologicals, License #1617
- Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 years of age and older.
November 27, 2013 Approval Letter - Boostrix[ARCHIVED]
To change the product labeling in accordance with the guidance issued on March 11, 2013.
February 13, 2013 Approval Letter - Boostrix
To include changes to the Full Prescribing Information to update the Postmarketing Experience section.
September 26, 2012 Approval Letter - Boostrix
To include a change in the Pregnany Category designation in the package insert from Category C to Category B.
September 10, 2012 Approval Letter - Boostrix March 12, 2012 Approval Letter- Boostrix
To include changes to the package insert to include "syncope" to the Warnings and Precaution section in Highlights and the Full Prescribing Information.
- July 8, 2011 Summary Basis for Regulatory Action - Boostrix (PDF - 115KB)
July 8, 2011 Approval Letter - Boostrix
To include immunogenicity and safety data to support the use of Boostrix® in individuals 65 years of age and older.
- March 17, 2011 Approval Letter - Boostrix
To revise package insert in the PLR format that includes clinical data describing the concomitant use of Boostrix® and Menactra®.
- December 1, 2010 Approval Letter - Boostrix
To revise labeling to address latex hypersensitivity in the Warnings and Precautions.
December 4, 2008 Approval Letter - Boostrix
To include single booster dose in adults 19-64 years of age for active immunization against tetanus, diphtheria, and pertussis.
December 29, 2005 Approval Letter - Boostrix
To include addition of clinical safety information to the package insert.
May 3, 2005 Approval Letter - Boostrix
Booster immunization against tetanus, diphtheria and pertussis as a single dose in adolescents 10-18 years of age.
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.